CA2274116A1 - Use, of an inhibitor of thioredoxin, for inhibiting tumor growth - Google Patents

Use, of an inhibitor of thioredoxin, for inhibiting tumor growth Download PDF

Info

Publication number
CA2274116A1
CA2274116A1 CA002274116A CA2274116A CA2274116A1 CA 2274116 A1 CA2274116 A1 CA 2274116A1 CA 002274116 A CA002274116 A CA 002274116A CA 2274116 A CA2274116 A CA 2274116A CA 2274116 A1 CA2274116 A1 CA 2274116A1
Authority
CA
Canada
Prior art keywords
thioredoxin
inhibitor
tumor growth
inhibiting tumor
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002274116A
Other languages
French (fr)
Other versions
CA2274116C (en
Inventor
Garth Powis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of University of Arizona
Original Assignee
Garth Powis
Arizona Board Of Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garth Powis, Arizona Board Of Regents filed Critical Garth Powis
Publication of CA2274116A1 publication Critical patent/CA2274116A1/en
Application granted granted Critical
Publication of CA2274116C publication Critical patent/CA2274116C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention re]ates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth.
CA002274116A 1996-12-06 1997-12-05 Use, of an inhibitor of thioredoxin, for inhibiting tumor growth Expired - Fee Related CA2274116C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3199596P 1996-12-06 1996-12-06
US60/031,995 1996-12-06
PCT/US1997/022292 WO1998024472A1 (en) 1996-12-06 1997-12-05 Uses of thioredoxin

Publications (2)

Publication Number Publication Date
CA2274116A1 true CA2274116A1 (en) 1998-06-11
CA2274116C CA2274116C (en) 2009-05-05

Family

ID=21862543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274116A Expired - Fee Related CA2274116C (en) 1996-12-06 1997-12-05 Use, of an inhibitor of thioredoxin, for inhibiting tumor growth

Country Status (3)

Country Link
EP (1) EP0946192A1 (en)
CA (1) CA2274116C (en)
WO (1) WO1998024472A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552060B1 (en) 1997-08-11 2003-04-22 Prolx Pharmaceuticals, Inc. Asymmetric disulfides and methods of using same
US6372772B1 (en) 1997-08-01 2002-04-16 Prolx Pharmaceuticals Corporation Inhibitors of redox signaling and methods of using same
IL137177A0 (en) 1998-01-30 2001-07-24 Genesense Technologies Inc Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
AU2003263795A1 (en) * 2002-08-02 2004-02-23 University Of Rochester Thioredoxin mutants and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903003D0 (en) * 1989-09-12 1989-09-12 Astra Ab NOVEL MEDICAL USE

Also Published As

Publication number Publication date
CA2274116C (en) 2009-05-05
WO1998024472A1 (en) 1998-06-11
EP0946192A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
AU3313589A (en) 17beta-n-monosubstituted carbamoyl or 17beta-acyl-4-aza- 5alpha-androst-1-en-3-ones as 5alpha reductase inhibitors
HU9401679D0 (en) Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors
IL108075A0 (en) Enzyme inhibitors
AU5533094A (en) Enzyme inhibitors
AU1301295A (en) Biocidal compositions and methods for treating commercial and recreational water
AU2582897A (en) Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AU6097094A (en) Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells
AU3901985A (en) Erythorbates as corrosion inhibitor in brine
EP0583074A3 (en) Angiotensin converting enzyme inhibitor and method for preparing same.
HK1020334A1 (en) Potassium channel inhibitors
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
AU3634695A (en) Surface active agents as gas hydrate inhibitors
AU3943793A (en) Methods of inhibiting or enhancing scar formation in the CNS
EP0670727A4 (en) Compounds that inhibit t cell proliferation and methods using the same.
AU5597098A (en) Inhibitors of the enzymatic activity of psa
AU3769097A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
EP0220107A3 (en) Use of angiotensin-converting enzyme inhibitors in macular degeneration
HK1033096A1 (en) Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculationdisorders
GB9315846D0 (en) Tumour inhibitors
AU6090594A (en) Angiotensin ii inhibitors
AU613302B2 (en) Quinolyloxazole-2-ones useful as proteinkinase c inhibitors
CA2158609A1 (en) 5 .alpha.-reductase inhibitors
EP0599514A3 (en) Pyranoquinoline derivatives as inhibitors of cell proliferation.
EP0858262A4 (en) Thrombin inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed